<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVES: P120-catenin (p120ctn) is a member of the E-cadherin-catenin cell-cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> complex </plain></SENT>
<SENT sid="1" pm="."><plain>Impairment of one or more of the components of this complex is associated with <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>The role of p120ctn in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> is not clear yet </plain></SENT>
<SENT sid="3" pm="."><plain>We studied the in vivo expression and cellular localization of p120ctn in <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> of the gastroesophageal junction </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Immunohistochemical staining for p120ctn was performed on 96 tumor samples, 20 cases of Barretts <z:mpath ids='MPATH_160'>metaplasia</z:mpath> and 13 lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The relationship with pathological characteristics and patient survival was also assessed </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Loss of <z:mpath ids='MPATH_458'>normal</z:mpath> surface p120ctn expression was found in 4/20 (20%) Barretts <z:mpath ids='MPATH_160'>metaplasia</z:mpath>, in 65/96 (68%) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, and 11/13 (85%) <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Nuclear immunoreactivity for p120ctn was seen in five <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Loss of <z:mpath ids='MPATH_458'>normal</z:mpath> expression of p120ctn was associated with a higher <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> grade (P &lt; 0.0001) but not with pTNM-stage </plain></SENT>
<SENT sid="9" pm="."><plain>Reduced expression of p120ctn was correlated with poor survival (P = 0.0002) </plain></SENT>
<SENT sid="10" pm="."><plain>Cox regression analysis showed that p120ctn is an independent prognostic marker </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Abnormal p120ctn expression is frequently seen in <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> of the gastroesophageal junction, and may be a useful as a prognostic marker in these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
</text></document>